GeneDx Holdings (WGS) Shares Outstanding (Weighted Average) (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $29.3 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $29.3 million, up 4.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $29.3 million (up 4.22% YoY), and the FY2025 annual result was $28.6 million, up 6.51% from the prior year.
• Shares Outstanding (Weighted Average) grew to $29.3 million in Q1 2026 per WGS's latest filing, from $28.6 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $29.3 million in Q1 2026 and troughed at $7.4 million in Q1 2022.
• A 5-year average of $22.5 million and a median of $26.1 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• On a YoY basis, Shares Outstanding (Weighted Average) climbed as much as 1435.89% in 2022 and fell as far as 93.79% in 2022.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $10.2 million in 2022, then soared by 137.49% to $24.3 million in 2023, then climbed by 10.61% to $26.9 million in 2024, then climbed by 6.51% to $28.6 million in 2025, then increased by 2.42% to $29.3 million in 2026.
• Business Quant data shows WGS's Shares Outstanding (Weighted Average) at $29.3 million in Q1 2026, $28.6 million in Q4 2025, and $28.8 million in Q3 2025.